Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource, 1 online resource.
Sprache
Englisch

Erschienen in
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer ; volume:23 ; number:1 ; day:30 ; month:6 ; year:2023 ; pages:1-9 ; date:12.2023
BMC cancer ; 23, Heft 1 (30.6.2023), 1-9, 12.2023

Urheber
Foldi, Julia
Tsagianni, Anastasia
Salganik, Max
Schnabel, Catherine A.
Brufsky, Adam
Londen, G. J. van
Pusztai, Lajos
Sanft, Tara
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12885-023-11104-w
URN
urn:nbn:de:101:1-2023092911442578428642
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:57 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Foldi, Julia
  • Tsagianni, Anastasia
  • Salganik, Max
  • Schnabel, Catherine A.
  • Brufsky, Adam
  • Londen, G. J. van
  • Pusztai, Lajos
  • Sanft, Tara
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer

Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer

Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer

Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer

Update Breast Cancer 2022 part 3 – Early-stage breast cancer

Update Breast Cancer 2022 part 3 – Early-stage breast cancer

Rat Models of Hormone Receptor-Positive Breast Cancer

Rat Models of Hormone Receptor-Positive Breast Cancer

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Circulating Tumor Cells in Early-Stage Breast Cancer

Circulating Tumor Cells in Early-Stage Breast Cancer

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer

Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer

Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer

Subtype-specific associations between breast cancer risk polymorphisms and the survival of early-stage breast cancer

Subtype-specific associations between breast cancer risk polymorphisms and the survival of early-stage breast cancer

Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer

Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer

The impact of CBP expression in estrogen receptor-positive breast cancer

The impact of CBP expression in estrogen receptor-positive breast cancer

Verbundene Objekte